Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $9
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $8 to $9.
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $8 to $9.